Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: A 3-year follow-up

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 42, Issue 6, 2011, Pages 1414-1422

  Desakorn, Varunee ^a   Karmacharya, Biraj Man ^a   Thanachartwet, Vipa ^a   Kyaw, Nyan Lin ^a   Tansuphaswadikul, Somsit ^b   Sahassananda, Duangjai ^a   Dhitavat, Jittima ^a   Maek A Nantawat, Wirach ^a   Pitisuttithum, Punnee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

Adverse effect; CD4 count; Effectiveness; GPO VIR; HIV

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL; THAILAND; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STAVUDINE; SURVIVAL ANALYSIS; THAILAND; TREATMENT OUTCOME;

EID: 84857660084     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Achananuparp S, Suriyawongpaisal P, Suebwonglee S, et al. Prevalence, detection and control of hypertension in Thai population of a central rural community. J Med Assoc Thai 1989;72(suppl 1):66-75.
2. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004;87:760-7. (Pubitemid 39166076)
3. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002;31:50-5.
4. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006;20:1163-9. (Pubitemid 43786105)
5. Centers for Disease Control and Prevention (CDC). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, 41:1-23.
6. Department of Health and Human Services (DHHS). DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bangkok: DHHS, 2009:1-161. [Cited 2011 Apr. 1]. Available from: URL: http://www.aidsinfo.nih. gov/ContentFiles/AdultsandAdolescentGL.pdf
7. Department of Health and Human Services (DHHS).2DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bangkok: DHHS, 2011:1-166. [Cited 2011 May 25]. Available from: URL: http://www.aidsinfo.nih. gov/ContentFiles/AdultsandAdolescentGL.pdf
8. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures - a meta-analysis. Int J STD AIDS 2008;19:291-6. (Pubitemid 351748268)
9. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9. (Pubitemid 32142299)
10. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4. (Pubitemid 28082255)
11. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23. (Pubitemid 32423219)
12. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global facts and figures 2009. [Cited 2011 May 25]. Available from: URL: http://data.unaids.org/ pub/Fact-Sheet/2009/20091124-FS-global-en.pdf
13. Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007;90:237-43. (Pubitemid 46377158)
14. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96:247-52.
15. Kline MW, Van Dyke RB, Lindsey JC, et al. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics 1998;101:214-20. (Pubitemid 28076653)
16. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS 2007;21:768-71. (Pubitemid 46568637)
17. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98. (Pubitemid 32662290)
18. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al. Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naïve advanced HIV-infected patients in Thailand: A prospective study. Curr Ther Res 2008;69:90-100. (Pubitemid 351446022)
19. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med 1992;20:80-93.
20. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
21. Phoolcharoen W, Kunanusont C, Pitisuttithum P, Bhamarapravati N. HIV/AIDS in Thailand. In: Lu Y, Essex M, eds. AIDS in Asia. New York: Plenum Publishers, 2004:3-33.
22. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acauir Immune Defic Syndr 2004;37:1566-9. (Pubitemid 39658193)
23. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS 1999;13:1659-67. (Pubitemid 30015713)
24. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405. (Pubitemid 34507951)
25. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acauir Immune Defic Syndr 2007;44:262-7. (Pubitemid 46328341)
26. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997;126:355-63. (Pubitemid 27102519)
27. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients. Southeast Asian J Trop Med Public Health 2005;36:362-9. (Pubitemid 40825537)
28. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO, 2010. [Cited 2010 Nov. 25]. Available from: URL: http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
29. Young J, Rickenbach M, Weber R, et al. Body fat changes among antiretroviral-nai've patients on PI-and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 2005;10:73-81. (Pubitemid 40767633)